Form 4: Bio-Rad CFO Reports RSU Vesting and Tax-Related Stock Sale

Bio-Rad Laboratories' EVP and CFO, Roop Kalyan Lakkaraju, disclosed the vesting of restricted stock units, the acquisition of shares, and a subsequent sale for tax obligations, alongside a new RSU grant.

Summary

• Roop Kalyan Lakkaraju, EVP, Chief Financial Officer of Bio-Rad Laboratories, Inc., reported transactions involving the company's Class A Common Stock and Restricted Stock Units (RSUs).
• On September 5, 2025, Lakkaraju was granted 5,480 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Bio-Rad Class A common stock. These RSUs vest over four years at 25% per year on the yearly anniversary date of the grant.
• On September 6, 2025, 1,535 Restricted Stock Units vested, resulting in the acquisition of 1,535 shares of Bio-Rad Class A Common Stock.
• Also on September 6, 2025, 550 shares of Bio-Rad Class A Common Stock were disposed of at a price of $295.43 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Lakkaraju beneficially owns 1,843.659 shares of Bio-Rad Class A Common Stock directly and 4,608 Restricted Stock Units directly.
• The reported beneficial ownership of common stock includes 13.2750 shares acquired under the Bio-Rad Employee Stock Purchase Plan on June 30, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The grant of new Restricted Stock Units (RSUs) indicates continued incentive alignment for the CFO, while the vesting and subsequent tax-related sale of shares are routine compensation events that do not significantly alter the company's fundamental outlook.

Positives

• The grant of 5,480 new Restricted Stock Units (RSUs) to the EVP, CFO, aligns management's interests with long-term shareholder value.
• The vesting of 1,535 RSUs indicates the achievement of prior compensation milestones.
• The acquisition of 1,535 shares of Class A common stock through RSU vesting increases the CFO's direct equity stake in the company.

Negatives

• The disposition of 550 shares of Class A common stock, valued at $295.43 per share, reduces the direct equity ownership of the EVP, CFO, although this was for tax withholding purposes.

Future Outlook

NA

Industry Context

This Form 4 filing details routine insider transactions related to executive compensation, specifically the vesting of restricted stock units and subsequent tax-related share sales. Such transactions are common across all industries for publicly traded companies with equity compensation plans and do not provide specific insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The transactions represent routine executive compensation and tax management, with minimal direct impact on existing shareholders beyond the slight dilution from RSU vesting (already accounted for in compensation plans).
• Employees: The filing highlights the company's use of equity compensation plans, which can be a positive for employee retention and motivation.

Next Steps

• The remaining 4,608 Restricted Stock Units held by the reporting person will continue to vest over four years at 25% per year on their yearly anniversary date of the grant.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, specifically the vesting of restricted stock units and a subsequent sale of shares for tax withholding. It does not contain information that would fundamentally alter the investment thesis for Bio-Rad Laboratories, Inc. Investors should rely on broader financial reports and strategic updates for investment decisions, maintaining a 'hold' position based solely on this filing.

Keywords

Bio-Rad Laboratories, BIO, BIO.B, Form 4, Insider Transaction, Restricted Stock Units, RSU, CFO, Stock Vesting, Equity Compensation, Tax Withholding